Compounds > camptothecin
Page last updated: 2024-08-22

camptothecin and Dysmyelopoietic Syndromes

camptothecin has been researched along with Dysmyelopoietic Syndromes in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cortes, JE; De Jager, RL; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, S; Kantarjian, HM; Thomas, DA1
Bourhis, JH; Damaj, G; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Ravoet, C; Ribrag, V; Suzan, F; Vantelon, JM1
Cortes, J; Faderl, S; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S1
Abbruzzese, JL; al-Bitar, M; Andreeff, M; Arbuck, S; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; Moore, M; O'Brien, S; Pierce, S1

Trials

4 trial(s) available for camptothecin and Dysmyelopoietic Syndromes

ArticleYear
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stomatitis; Topoisomerase I Inhibitors

2002
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Leukemia, 2003, Volume: 17, Issue:2

    Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Blast Crisis; Bone Marrow; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Time Factors

2003
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Cancer, 2006, Oct-01, Volume: 107, Issue:7

    Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome

2006
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Blood, 1996, Oct-01, Volume: 88, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Fever; Follow-Up Studies; Genes, ras; Humans; Leukemia, Myelomonocytic, Chronic; Life Tables; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Remission Induction; Stomatitis; Survival Analysis; Survival Rate; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome

1996

Other Studies

1 other study(ies) available for camptothecin and Dysmyelopoietic Syndromes

ArticleYear
Hycamtin achieves promising results in study of patients with leukemia.
    Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Ovarian Neoplasms; Remission Induction; Topotecan

1996